CD19 and neoplasm: This study found that mice injected with the anti-CD19 CAR EVs loaded with MYC-CRISPR had slowed tumor growth compared with those injected with MYC-CRISPR-loaded EVs without CAR modifications, and the tumor cell damage was observed in immunohistochemical studies [24].